Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Johnson & Johnson) is now approved as a once-monthly subcutaneous injection for the first-line treatment of epidermal growth factor receptor (EGFR ...

If approved, a subcutaneous formulation of anifrolumab would allow patients the ability to self-administer the medication outside of a hospital or clinic setting. The Food and Drug Administration (FDA ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...

Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...

According to Lilly, the single-injection, citrate-free, maintenance dose will be available in the US as a prefilled pen or prefilled syringe in early 2026. The Food and Drug Administration (FDA) has ...

“With today’s approval, guselkumab is the first IL-23 inhibitor to offer inflammatory bowel disease patients robust clinical and endoscopic results with a fully subcutaneous induction dose regimen, ...

What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...

New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...

Patients can now receive treatment in as little as one to two minutes, compared to a 30-minute IV infusion New option offers greater convenience and flexibility in treatment settings, from hospitals ...